Tundra Space

Tundra Space

Clinical Research Directory

Browse clinical research sites, groups, and studies.

Back to Studies
RECRUITING
NCT07318558
PHASE3

A Clinical Trial of Sac-TMT in People With Non-HRD Positive Advanced Ovarian Cancer (MK-2870-021)

Sponsor: Merck Sharp & Dohme LLC

View on ClinicalTrials.gov

Summary

Researchers are looking for new ways to treat ovarian cancer (OC). Current treatment for OC may start with surgery to remove as much of the cancer as possible. After surgery, people may receive chemotherapy. After chemotherapy, standard care options may include: * Maintenance treatment, which is used after another therapy to keep the cancer from growing, spreading, or coming back. Bevacizumab is a targeted therapy used as standard maintenance treatment. Targeted therapy works to control how specific types of cancer cells grow and spread. * Observation, which is watching to see if cancer grows or worsens The study medicine, sacituzumab tirumotecan (also called sac-TMT), is a targeted therapy. The goal of this study is to learn if people who receive sac-TMT maintenance treatment with or without bevacizumab live longer without the cancer getting worse than people who receive standard care.

Official title: A Phase 3, Randomized, Open-label, Multicenter Study of Sacituzumab Tirumotecan (Sac-TMT, MK-2870) Maintenance Treatment With or Without Bevacizumab Versus Standard of Care in Participants With Newly Diagnosed Advanced Non-HRD Positive Ovarian Cancer Following First-line Platinum-based Chemotherapy (TroFuse-021/ENGOTov85/GOG-3102)

Key Details

Gender

FEMALE

Age Range

18 Years - Any

Study Type

INTERVENTIONAL

Enrollment

900

Start Date

2026-02-16

Completion Date

2033-02-25

Last Updated

2026-04-02

Healthy Volunteers

No

Interventions

DRUG

Sacituzumab tirumotecan

Administered via intravenous (IV) infusion at a dose of 4mg/kg

DRUG

Bevacizumab

Administered via IV infusion at a dose of 15mg/kg

DRUG

Rescue Medications

Participants must receive prophylactic steroid mouthwash (dexamethasone or equivalent). It is recommended that participants receive the following rescue medications prior to sac-TMT infusion, per approved product label: histamine-1 receptor antagonist, histamine-2 receptor antagonist, acetaminophen or equivalent, and dexamethasone or equivalent.

Locations (13)

Mount Sinai Cancer Center ( Site 0029)

Miami Beach, Florida, United States

Rambam Health Care Campus ( Site 1422)

Haifa, Israel

Edith Wolfson Medical Center ( Site 1423)

Holon, Israel

Iwate Medical University Hospital ( Site 1610)

Shiwa-gun, Iwate, Japan

Saitama Medical University International Medical Center ( Site 1607)

Hidaka, Saitama, Japan

Cancer Institute Hospital of JFCR ( Site 1614)

Koto, Tokyo, Japan

Niigata Cancer Center Hospital ( Site 1608)

Niigata, Japan

Severance Hospital ( Site 2302)

Seodaemun-Gu, Seoul, South Korea

Keimyung University Dongsan Hospital ( Site 2304)

Daegu, Taegu-Kwangyokshi, South Korea

Seoul National University Hospital ( Site 2301)

Seoul, South Korea

Asan Medical Center ( Site 2305)

Seoul, South Korea

Samsung Medical Center ( Site 2303)

Seoul, South Korea

Linkou Chang Gung Memorial Hospital ( Site 2605)

Taoyuan District, Taiwan